Biostar Pharma Successively Achieved First Patient Dosing for Two Phase II/III Multiregional Clinical Trials of Utidelone Capsule (UTD2)
SAN FRANCISCO, Sept. 15, 2025 /PRNewswire/ -- Biostar Pharma, Inc., the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. ("Biostar", Stock Code: 2563.HK) which is a synthetic biology driven biopharma company focusing on the discovery, development and commercialization of innovative oncology drugs, is pleased to announce that the first patients have been dosed for two phase II/III multiregional clinical...
Rona Therapeutics Announces IND Filing of RN3161, a Highly Potent and Durable INHBE siRNA for Obesity
SHANGHAI and SANTA BARBARA, Calif., Sept. 15, 2025 /PRNewswire/ -- Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, announced today the successful submission of RN3161 to the Australian Human Research Ethics Committee (HREC). RN3161 is a proprietary GalNAc-conjugated siRNA targeting INHBE, a novel therapeutic mechanism for adults with overweight and obesity. Obesity is a global health crisis,...
FutureCeuticals Files Lawsuit Against NeuroRush Owner for Patent Infringement over Alleged Copycat Ingredient
MOMENCE, Ill., Sept. 15, 2025 /PRNewswire/ -- VDF FutureCeuticals, Inc. filed a lawsuit against Aura Scientific, asserting that its brain performance ingredient NeuroRush – an extract of whole coffee fruit – infringes multiple of FutureCeuticals' patents covering technology relating to coffee fruit, including patents relating to the use of coffee fruit compositions...
Sunsred Launches FDA-cleared Red Light Therapy Devices for Wellness Brands Worldwide
SHENZHEN, China, Sept. 15, 2025 /PRNewswire/ -- Shenzhen Sunsred Technology Co., Ltd. is shaking things up in the wellness tech world with its latest lineup of red light therapy devices. As a go-to OEM/ODM red light therapy manufacturer in this space, Sunsred is meeting the huge global demand for safe, effective, and certified light therapy solutions. The new range...
Medit Link Express for iPad Debuts as Medit i900 Mobility Goes into Shipping
SEOUL, South Korea, Sept. 15, 2025 /PRNewswire/ -- Medit (www.medit.com), a global leader in digital dentistry, today announced two milestone moments for the industry. The company has officially launched Medit Link Express, its first iPad-native app for intraoral scanning, now available on the Apple App Store, and at the same time begun...
Clinically Proven Human Milk Probiotic LC40® supports Infant Health and Breastfeeding Mothers
SINGAPORE, Sept. 15, 2025 /PRNewswire/ -- Supported by six clinical studies and two safety trials, Kerry's LC40® is the first probiotic strain of its kind validated for both infant and maternal applications, offering a natural, science-backed approach to early life and maternal health. Human milk probiotics bridges nature...
Akeso Announces First Patient Dose in Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma
HONG KONG, Sept. 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its global, multicenter, randomized Phase II registrational trial (COMPASSION-36/AK104-225). The trial will evaluate cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, in combination with lenvatinib versus lenvatinib alone for the treatment of advanced hepatocellular carcinoma (HCC) in...
Jointly discovered KAT6i molecule originating from Australian research has initiated Phase 3 in HR+ HER2- Breast Cancer with Pfizer Inc
Australian scientists who discovered how to "turn off" genes that make cancer cells grow are celebrating the next phase of development – with Pfizer's first in class KAT6 inhibitor PF-07248144 now moving to the next stages of clinical investigation. MELBOURNE, Australia, Sept. 15, 2025 /PRNewswire/ -- Australian biotechnology investment and commercialisation incubator, Oncology One Pty Ltd, is pleased to...
New Data, iCARE Study: Hailie® Smartinhaler® Powers Unprecedented Medication Adherence in Patients with COPD and Asthma
Highlights: Up to 235% increase in real-world adherence compared to published norms (20–40%), across ~850 chronic obstructive pulmonary disease (COPD) and asthma patients. >60% patients achieved an average two-week baseline adherence with ~4 in 10 patients reaching the critical threshold of >80% adherence, a level associated with 50% fewer exacerbations and lower hospitalisations. Sustained engagement of 12+ months...
MGI Tech Introduces DNBSEQ-T7+: A Next-Generation ‘Data Mining Machine’ for Genomics
SHENZHEN, China, Sept. 15, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a company dedicated to developing core tools and technologies that drive innovation in life sciences, announced the launch of the DNBSEQ-T7+, its latest high-throughput sequencer. Designed to meet the rising demand for large-scale genomic research, the T7+ delivers more than 14 Tb/day of...
